Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth

Zhang, Ruijie; Roque, Dana M.; Reader, Jocelyn; Lin, Jiayuh

doi:10.3892/ijo.2022.5340

Cited by 18 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The viability was evaluated using an MTT Assay Kit (Beyotime) 23 . Briefly, TPC‐1 and CAL‐62 cells were cultured in a 48‐well plate (3 × 10 3 cells/well).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway

Jiang

Guan

Zheng

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction: Thyroid cancer has received increasing attention; however, its detailed pathogenesis and pathological processes remain unclear. We investigated the role of TANK-binding kinase 1 (TBK1) in the progression of thyroid cancer. Methods: The expression of TBK1 in thyroid cancer and normal control tissues was analyzed using real-time quantitative polymerase chain reaction. The function of TBK1 on thyroid cancer cells was detected using MTT, colony formation, wound healing, and Transwell assays. The xenograft assay was carried out to check on the role of TBK1 in thyroid cancer.Results: TBK1 was highly expressed in thyroid tumors. High expression of TBK1 raised viability, proliferation, migration, and invasion of thyroid cancer cells. Gene set enrichment analysis revealed that TBK1 activated the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin pathway. In addition, Myc-associated zinc finger protein (MAZ) was overexpressed in thyroid cancer and transcriptionally activated BK1. MAZ silence reversed the effects of TBK1 overexpression on thyroid cancer progression. Cotransfection with MAZ small-interfering RNA(siRNA) and TBK1 siRNA did not strengthen the inhibitory effect of TBK1 silencing on the thyroid cancer cells. The xenograft tumor assay showed that TBK1 short hairpinRNA inhibited tumor growth. Conclusion: MAZ silencing inhibited tumor progress of thyroid cancer cells, whereas this inhibitory effect was reversed by TBK1 overexpression.

show abstract

“…The viability was evaluated using an MTT Assay Kit (Beyotime) 23 . Briefly, TPC‐1 and CAL‐62 cells were cultured in a 48‐well plate (3 × 10 3 cells/well).…”

Section: Methodsmentioning

confidence: 99%

“…The viability was evaluated using an MTT Assay Kit (Beyotime). 23 Briefly, TPC-1 and CAL-62 cells were cultured in a 48-well plate (3 × 10 3 cells/well). The MTT reagent was added when the culture reached a specific time point and incubated for 4 h, followed by the addition of dimethyl sulfoxide solution.…”

Section: Mtt Assaymentioning

confidence: 99%

TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway

Jiang

Guan

Zheng

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…Simultaneous inhibition of IL-6 and IL-8 receptors via Tocilizumab and Reparixin (inhibitor of C-X-C motif chemokine receptor 1) significantly decreased the expression of matrix metalloprotease in mouse MDA-MB-231 breast cancer model models and decreased the incidence of liver and lung metastasis [ 122 ]. Similarly, a combination of bazedoxifene and SCH527123 (inhibitor of C-X-C motif chemokine receptors; Il-8 receptors) synergically repressed STAT3 and Akt phosphorylation in ovarian cancer cells (OVCAR3, SKOV3, and CAOV3) and in mice bearing CAOV3 tumours when compared to agents inhibiting just IL-6 or IL-8 [ 123 ]. According to the proposed model, in this case, the effect of combination therapy on tumour growth was sometimes smaller compared to the application of single agents.…”

Section: Inhibition Of Il-6 Signalling In Combination Therapymentioning

confidence: 99%

The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities

Rašková

Lacina

Kejík

et al. 2022

Cells

View full text Add to dashboard Cite

Interleukin 6 (IL-6) belongs to a broad class of cytokines involved in the regulation of various homeostatic and pathological processes. These activities range from regulating embryonic development, wound healing and ageing, inflammation, and immunity, including COVID-19. In this review, we summarise the role of IL-6 signalling pathways in cancer biology, with particular emphasis on cancer cell invasiveness and metastasis formation. Targeting principal components of IL-6 signalling (e.g., IL-6Rs, gp130, STAT3, NF-κB) is an intensively studied approach in preclinical cancer research. It is of significant translational potential; numerous studies strongly imply the remarkable potential of IL-6 signalling inhibitors, especially in metastasis suppression.

show abstract

“…However, on the basis of experimental data, we can hypothesise that simultaneous blocking of other factors might be more promising, e.g. simultaneous inhibition of IL-6 and IL-8 (Jobe et al 2016;Plzák et al 2019;Zhang et al 2022). For example, the combination of bazedoxifene (gp130 inhibitor) and paclitaxel seems to be potentially suitable for the therapy of ovarian cancer (Park et al 2022).…”

Section: Role Of Il-6 and Other Inflammation-supporting Factorsmentioning

confidence: 99%

Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation

Gál

Brábek

Holub

et al. 2022

Histochem Cell Biol

View full text Add to dashboard Cite

Recent evidence indicates that targeting IL-6 provides broad therapeutic approaches to several diseases. In patients with cancer, autoimmune diseases, severe respiratory infections [e.g. coronavirus disease 2019 (COVID-19)] and wound healing, IL-6 plays a critical role in modulating the systemic and local microenvironment. Elevated serum levels of IL-6 interfere with the systemic immune response and are associated with disease progression and prognosis. As already noted, monoclonal antibodies blocking either IL-6 or binding of IL-6 to receptors have been used/tested successfully in the treatment of rheumatoid arthritis, many cancer types, and COVID-19. Therefore, in the present review, we compare the impact of IL-6 and anti-IL-6 therapy to demonstrate common (pathological) features of the studied diseases such as formation of granulation tissue with the presence of myofibroblasts and deposition of new extracellular matrix. We also discuss abnormal activation of other wound-healing-related pathways that have been implicated in autoimmune disorders, cancer or COVID-19.

show abstract

Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth

Cited by 18 publications

References 50 publications

TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway

TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway

The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities

Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation

Contact Info

Product

Resources

About